ArticleGastro hep advances2026
Development of a Neural Network to Detect Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Interpretable Machine Learning Models for Early Detection of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Non-Invasive Routine Clinical and Laboratory Data.International journal of general medicine · 2026Article
- Multiorgan crosstalk in MASLD/MASH: from hepatic pathogenesis to systemic complications.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Early identification of metabolic dysfunction-associated steatotic liver disease (MASLD) is critical for risk stratification and timely intervention. Conventional noninvasive indices (fatty liver index, hepatic steatosis index, Zhejiang University index, and MASLD index) are limited by linear assumptions and moderate predictive accuracy. We aimed to develop and externally validate a neural network model for noninvasive detection of hepatic steatosis. Methods: We used a retrospective cohort of 17,465 Japanese health checkup participants (2010-2020). All clinical data were obtained at the Ehime General Health Care Association. The cohort was split into a development cohort (n = 8426) and an internal validation cohort (n = 9039). A feedforward neural network was trained using clinical and biochemical variables, including body mass index, abdominal circumference, and existing indices. External validation used the Third National Health and Nutrition Examination Survey cohort (n = 9759), with hepatic steatosis defined by ultrasonography (Gallbladder and Upper Abdominal Ultrasound Hepatic Steatosis Profile Rating≥2). Model performance was assessed via area under the receiver operating characteristic curve, calibration, decision curve analysis, and subgroup analyses. Results: The neural network achieved an area under the receiver operating characteristic curve of 0.922 (95% confidence interval: 0.913-0.931) in internal validation and 0.924 (95% confidence interval: 0.917-0.931) in external validation, outperforming fatty liver index, hepatic steatosis index, Zhejiang University index, and MASLD indices (all Conclusion: Our neural network model outperforms conventional indices in detecting moderate-to-severe hepatic steatosis and may facilitate early, scalable MASLD screening in primary care and low-resource settings.UMIN No. 11953.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.